PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 184 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $491,000 | -98.2% | 10,311 | -98.7% | 0.05% | -96.2% |
| Q3 2016 | $26,638,000 | +12.3% | 778,442 | +10.7% | 1.22% | +10.7% |
| Q2 2016 | $23,714,000 | -38.9% | 703,054 | -4.1% | 1.10% | -39.7% |
| Q1 2016 | $38,828,000 | +9.6% | 732,887 | +58.8% | 1.83% | +19.8% |
| Q4 2015 | $35,432,000 | +55.6% | 461,422 | +80.1% | 1.53% | +91.1% |
| Q1 2015 | $22,767,000 | -54.2% | 256,244 | -54.3% | 0.80% | -55.3% |
| Q4 2014 | $49,667,000 | -33.3% | 560,200 | -27.1% | 1.79% | -32.0% |
| Q3 2014 | $74,472,000 | -16.2% | 768,396 | -20.6% | 2.63% | -7.6% |
| Q2 2014 | $88,887,000 | +5.8% | 967,638 | -19.4% | 2.85% | +14.2% |
| Q1 2014 | $84,004,000 | +73.4% | 1,200,229 | +42.4% | 2.50% | +86.1% |
| Q4 2013 | $48,446,000 | +211.9% | 842,702 | +160.9% | 1.34% | +200.7% |
| Q3 2013 | $15,534,000 | – | 323,027 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |